drugset / Trial / NCT04392232

A Study of COVID 19 Convalescent Plasma in High Risk Patients With COVID 19 Infection

NCT04392232

Phase 2 Completed 159 enrolled TriHealth Inc.
NaSingle-groupOpen-labelTreatment

Summary

Purpose of Study • The purpose of this study to evaluate, the effectiveness of convalescent plasma in combatting the symptoms and effects of the coronavirus disease, COVID-19. Beyond supportive care, there are no proven treatment options for COVID-19.

Timeline

Start
2020-05-05
Primary completion
2021-09-21
Completion
2021-09-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Convalescent Plasma Protein / enzyme biologic

Indications